Tenofovir
DefinitionThis section has been translated automatically.
Virustatic agent (nucleotide analogue). A nucleotide inhibitor of the reverse transcriptase of HIV.
Half-lifeThis section has been translated automatically.
12-18 hours.
IndicationThis section has been translated automatically.
Antiretroviral combination therapy for the treatment of HIV-1 infection in treatment-naive or previously treated patients. Also approved as a combination preparation with emtricitabine (FTC) for HIV-PrEP.
Pregnancy/nursing periodThis section has been translated automatically.
Strict indication in pregnancy (insufficient data), contraindicated in lactation (preparation passes into breast milk and insufficient data).
Dosage and method of useThis section has been translated automatically.
Adults/young people > 18 years: 1 time per day 1 tbl. p.o. with a meal. In case of swallowing difficulties, take the tablet dissolved in at least 100 ml of water, orange or grape juice.
Undesirable effectsThis section has been translated automatically.
Very often light or moderate gastrointestinal complaints (nausea, diarrhoea, vomiting, flatulence).
InteractionsThis section has been translated automatically.
Drugs whose active secretion in the kidney takes place via anion transporters (e.g. cidofovir), lopinavir/ritonavir, didanosine.
ContraindicationThis section has been translated automatically.
Pat. < 18 years, hypersensitivity to Tenofovir or other components of the preparation.
PreparationsThis section has been translated automatically.
Viread